摘要
The impact of long-term nucleos(t)ide analogs treatment on host metabolism is a concern. Hence, we conducted this study to compare the effect of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) on metabolic parameters among chronic hepatitis B (CHB) patients. In this real-life retrospective study, 2030 CHB outpatients treated with ETV or TDF at Nanfang Hospital, China, were included. For treatment-naive patients, pretreatment and semiannual metabolic parameters were collected. For treatment-experienced patients, metabolic parameters were collected at the first visit. Propensity score matching (PSM) was used to balance the effects of potential confounding factors. Among 122 treatment-naive patients and 1908 treatment-experienced patients, ETV-treated patients were older with a higher percentage of metabolic syndrome. After PSM, the characteristics were comparable between the two groups. For treatment-naive patients, four lipid parameters, including total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein, and triglyceride levels showed a decreasing trend during the 42-month TDF treatment, while they remained relatively stable or increased during ETV treatment. At Month 30, the levels of TC and LDL among TDF-treated patients were significantly lower than those among ETV-treated patients (TC: 4.7 mmol/L vs. 3.9 mmol/L, p = 0.004; LDL: 3.0 mmol/L vs. 2.4 mmol/L, p = 0.009). For treatment-experienced patients, we also observed lower levels of lipid parameters in patients with different durations of TDF treatment. The levels of glucose and uric acid were similar among ETV- and TDF-treated patients. TDF has a lipid-lowering effect in CHB patients, which provides a basis for the selection of antiviral drugs for aging CHB patients.
学科与关键词
- Comparison of Efficacy and Safety of Tenofovir and Entecavir in Chronic Hepatitis B Virus Infection: A Systematic Review and Meta-AnalysisKe Weixia; Liu Li; Zhang Chi; Ye Xiaohua; Gao Yanhui; Zhou Shudong; Yang Yi*PLoS ONE, 2014, 9(6): e98865.
- Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough?Liang, Xieer; Xie, Qing; Shang, Jia; Tang, Hong; Xu, Min; Meng, Qinghua; Zhang, Jiming; Gao, Pujun; Sheng, Jifang; Wang, Hao; Jia, Jidong; Wang, Guiqiang; Wu, Shunquan; Ping, Jingna; Hou, Jinlin*Journal of Gastroenterology and Hepatology, 2022, 37(3): 471-479.
- Effects of entecavir and tenofovir disoproxil fumarate on the incidence and severity of COVID-19 in patients with chronic hepatitis BLiao, Xingmei; Fan, Yujie; Zhong, Chunxiu; Zhao, Siru; Guo, Liangxu; Tan, Wenjuan; Yin, Junhua; Fan, Rong*BMC INFECTIOUS DISEASES, 2023, 23(1): 843.
